Organ-on-a-chip (OOAC) has attracted great attention during the last decade as a revolutionary alternative to conventional animal models. This cutting-edge technology has also brought constructive changes to the field of cardiovascular research. The cardiovascular system, especially the heart as a well-protected vital organ, is virtually impossible to replicate in vitro with conventional approaches. This made scientists assume that they needed to use animal models for cardiovascular research. However, the frequent failure of animal models to correctly reflect the native cardiovascular system necessitated a search for alternative platforms for preclinical studies. Hence, as a promising alternative to conventional animal models, OOAC technology is being actively developed and tested in a wide range of biomedical fields, including cardiovascular research. Therefore, in this review, the current literature on the use of OOACs for cardiovascular research is presented with a focus on the basis for using OOACs, and what has been specifically achieved by using OOACs is also discussed. By providing an overview of the current status of OOACs in cardiovascular research and its future perspectives, we hope that this review can help to develop better and optimized research strategies for cardiovascular diseases (CVDs) as well as identify novel applications of OOACs in the near future.
Get full access to this article
View all access options for this article.
References
1.
RothGA, MensahGA, JohnsonCO, AddoloratoG, AmmiratiE, BaddourLM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76:2982–3021.
2.
LibbyP. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–51.
ViraniSS, AlonsoA, AparicioHJ, BenjaminEJ, BittencourtMS, CallawayCW, et al. Heart Disease and Stroke Statistics-Update: A Report From the American Heart Association. Circulation. 2021;143:e254–e743.
5.
FusterV. Top 10 cardiovascular therapies and interventions for the next decade. Nat Rev Cardiol. 2014;11:671–83.
6.
Van NormanGA. Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM’s Law. JACC Basic Transl Sci. 2017;2:613–25.
7.
CookD, BrownD, AlexanderR, MarchR, MorganP, SatterthwaiteG, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13:419–31.
8.
ScannellJW, BlanckleyA, BoldonH, WarringtonB. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200.
9.
RingelMS, ShahNA, BaedekerM, LimCT, LamichhaneA, SchulzeU. Occlusion in the Flow of New Drugs for Cardiovascular Disease. Clin Pharmacol Ther. 2017;102:246–53.
10.
PaulSM, MytelkaDS, DunwiddieCT, PersingerCC, MunosBH, LindborgSR, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9:203–14.
11.
KolaI, LandisJ. Can the pharmaceutical industry reduce attrition rates?Nat Rev Drug Discov. 2004;3:711–5.
12.
PoundP, EbrahimS, SandercockP, BrackenMB, RobertsI, Reviewing Animal Trials Systematically G. Where is the evidence that animal research benefits humans?BMJ. 2004;328:514–7.
13.
WalshMG, SawleshwarkarS, HossainS, MorSM. Whence the next pandemic? The intersecting global geography of the animal-human interface, poor health systems and air transit centrality reveals conduits for high-impact spillover. One Health. 2020;11:100177.
14.
HolmesA, BonnerF, JonesD. Assessing drug safety in human tissues - what are the barriers?Nat Rev Drug Discov. 2015;14:585–7.
15.
DahlinJL, IngleseJ, WaltersMA. Mitigating risk in academic preclinical drug discovery. Nat Rev Drug Discov. 2015;14:279–94.
16.
WangY, WangP, QinJ. Microfluidic Organs-on-a-Chip for Modeling Human Infectious Diseases. Acc Chem Res. 2021;54:3550–62.
17.
GaliePA, NguyenDH, ChoiCK, CohenDM, JanmeyPA, ChenCS. Fluid shear stress threshold regulates angiogenic sprouting. Proc Natl Acad Sci U S A. 2014;111:7968–73.
18.
WangL, LiuW, WangY, WangJC, TuQ, LiuR, et al. Construction of oxygen and chemical concentration gradients in a single microfluidic device for studying tumor cell-drug interactions in a dynamic hypoxia microenvironment. Lab Chip. 2013;13:695–705.
19.
SungJH, ShulerML. A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip. 2009;9:1385–94.
20.
ReardonS. ‘Organs-on-chips’ go mainstream. Nature. 2015;523:266.
21.
AlepeeN, BahinskiA, DaneshianM, De WeverB, FritscheE, GoldbergA, et al. State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX. 2014;31:441–77.
MaQ, MaH, XuF, WangX, SunW. Microfluidics in cardiovascular disease research: state of the art and future outlook. Microsyst Nanoeng. 2021;7:19.
24.
SchimekK, BusekM, BrinckerS, GrothB, HoffmannS, LausterR, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588–98.
25.
ChenMB, SrigunapalanS, WheelerAR, SimmonsCA. A 3D microfluidic platform incorporating methacrylated gelatin hydrogels to study physiological cardiovascular cell-cell interactions. Lab Chip. 2013;13:2591–8.
26.
van der MeerAD, OrlovaVV, ten DijkeP, van den BergA, MummeryCL. Three-dimensional co-cultures of human endothelial cells and embryonic stem cell-derived pericytes inside a microfluidic device. Lab Chip. 2013;13:3562–8.
27.
RyuH, OhS, LeeHJ, LeeJY, LeeHK, JeonNL. Engineering a Blood Vessel Network Module for Body-on-a-Chip Applications. J Lab Autom. 2015;20:296–301.
28.
HasenbergT, MuhlederS, DotzlerA, BauerS, LabudaK, HolnthonerW, et al. Emulating human microcapillaries in a multi-organ-chip platform. J Biotechnol. 2015;216:1–10.
29.
ZhangW, ZhangYS, BakhtSM, AlemanJ, ShinSR, YueK, et al. Elastomeric free-form blood vessels for interconnecting organs on chip systems. Lab Chip. 2016;16:1579–86.
30.
ZhangB, MontgomeryM, ChamberlainMD, OgawaS, KoroljA, PahnkeA, et al. Biodegradable scaffold with built-in vasculature for organ-on-a-chip engineering and direct surgical anastomosis. Nat Mater. 2016;15:669–78.
31.
WangX, PhanDT, SobrinoA, GeorgeSC, HughesCC, LeeAP. Engineering anastomosis between living capillary networks and endothelial cell-lined microfluidic channels. Lab Chip. 2016;16:282–90.
32.
UrbaczekAC, LeaoP, SouzaFZR, AfonsoA, Vieira AlbericeJ, CappeliniLTD, et al. Endothelial Cell Culture Under Perfusion On A Polyester-Toner Microfluidic Device. Sci Rep. 2017;7:10466.
33.
AbudupataerM, ChenN, YanS, AlamF, ShiY, WangL, et al. Bioprinting a 3D vascular construct for engineering a vessel-on-a-chip. Biomed Microdevices. 2019;22:10.
34.
JiaL, HanF, YangH, TurnbullG, WangJ, ClarkeJ, et al. Microfluidic Fabrication of Biomimetic Helical Hydrogel Microfibers for Blood-Vessel-on-a-Chip Applications. Adv Healthc Mater. 2019;8:e1900435.
35.
Rajeeva PandianNK, WaltherBK, SureshR, CookeJP, JainA. Microengineered Human Vein-Chip Recreates Venous Valve Architecture and Its Contribution to Thrombosis. Small. 2020;16:e2003401.
36.
PriyadarshaniJ, RoyT, DasS, ChakrabortyS. Frugal Approach toward Developing a Biomimetic, Microfluidic Network-on-a-Chip for In vitro Analysis of Microvascular Physiology. ACS Biomater Sci Eng. 2021;7:1263–77.
37.
CarmelietP, JainRK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307.
AbaciHE, ShenYI, TanS, GerechtS. Recapitulating physiological and pathological shear stress and oxygen to model vasculature in health and disease. Sci Rep. 2014;4:4951.
40.
CapulliAK, TianK, MehandruN, BukhtaA, ChoudhurySF, SuchytaM, et al. Approaching the in vitro clinical trial: engineering organs on chips. Lab Chip. 2014;14:3181–6.
KimS, KimW, LimS, JeonJS. Vasculature-On-A-Chip for In vitro Disease Models. Bioengineering (Basel). 2017;4.
43.
WuMH, HuangSB, CuiZ, CuiZ, LeeGB. A high throughput perfusion-based microbioreactor platform integrated with pneumatic micropumps for three-dimensional cell culture. Biomed Microdevices. 2008;10:309–19.
44.
MenonNV, SuC, PangKT, PhuaZJ, TayHM, DalanR, et al. Recapitulating atherogenic flow disturbances and vascular inflammation in a perfusable 3D stenosis model. Biofabrication. 2020;12:045009.
45.
KimS, LeeH, ChungM, JeonNL. Engineering of functional, perfusable 3D microvascular networks on a chip. Lab Chip. 2013;13:1489–500.
46.
KachgalS, PutnamAJ. Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms. Angiogenesis. 2011;14:47–59.
47.
LinL, ChungCK. PDMS Microfabrication and Design for Microfluidics and Sustainable Energy Application: Review. Micromachines (Basel). 2021;12.
48.
ColtroWK, da SilvaJA, CarrilhoE. Fabrication and integration of planar electrodes for contactless conductivity detection on polyester-toner electrophoresis microchips. Electrophoresis. 2008;29:2260–5.
49.
RussoR, MalinconicoM, SantagataG. Effect of cross-linking with calcium ions on the physical properties of alginate films. Biomacromolecules. 2007;8:3193–7.
50.
PijnenborgR, VercruysseL, HanssensM. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006;27:939–58.
51.
MeiX, GlueckertR, Schrott-FischerA, LiH, LadakHM, AgrawalSK, et al. Vascular Supply of the Human Spiral Ganglion: Novel Three-Dimensional Analysis Using Synchrotron Phase-Contrast Imaging and Histology. Sci Rep. 2020;10:5877.
52.
Vunjak NovakovicG, EschenhagenT, MummeryC. Myocardial tissue engineering: in vitro models. Cold Spring Harb Perspect Med. 2014;4.
53.
CimettaE, Godier-FurnemontA, Vunjak-NovakovicG. Bioengineering heart tissue for in vitro testing. Curr Opin Biotechnol. 2013;24:926–32.
54.
AgarwalA, GossJA, ChoA, McCainML, ParkerKK. Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip. 2013;13:3599–608.
55.
McCainML, SheehySP, GrosbergA, GossJA, ParkerKK. Recapitulating maladaptive, multiscale remodeling of failing myocardium on a chip. Proc Natl Acad Sci U S A. 2013;110:9770–5.
56.
LoskillP, MarcusSG, MathurA, ReeseWM, HealyKE. muOrgano: A Lego(R)-Like Plug & Play System for Modular Multi-Organ-Chips. PLoS One. 2015;10:e0139587.
57.
SkardalA, MurphySV, DevarasettyM, MeadI, KangHW, SeolYJ, et al. Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform. Sci Rep. 2017;7:8837.
58.
SheehySP, GrosbergA, QinP, BehmDJ, FerrierJP, EaglesonMA, et al. Toward improved myocardial maturity in an organ-on-chip platform with immature cardiac myocytes. Exp Biol Med (Maywood). 2017;242:1643–56.
59.
UgoliniGS, VisoneR, Cruz-MoreiraD, MainardiA, RasponiM. Generation of functional cardiac microtissues in a beating heart-on-a-chip. Methods Cell Biol. 2018;146:69–84.
60.
BudhathokiS, GrahamC, SethuP, KannappanR. Engineered Aging Cardiac Tissue Chip Model for Studying Cardiovascular Disease. Cells Tissues Organs. 2021:1–12.
61.
Cruz-MoreiraD, VisoneR, Vasques-NovoaF, ASB, Leite-MoreiraA, RedaelliA, et al. Assessing the influence of perfusion on cardiac microtissue maturation: A heart-on-chip platform embedding peristaltic pump capabilities. Biotechnol Bioeng. 2021;118:3128–37.
62.
HoCY. Hypertrophic cardiomyopathy: preclinical and early phenotype. J Cardiovasc Transl Res. 2009;2:462–70.
63.
SergeevaIA, ChristoffelsVM. Regulation of expression of atrial and brain natriuretic peptide, biomarkers for heart development and disease. Biochim Biophys Acta. 2013;1832:2403–13.
64.
KelsoEJ, GeraghtyRF, McDermottBJ, TrimbleER, NichollsDP, SilkeB. Mechanical effects of ET-1 in cardiomyocytes isolated from normal and heart-failed rabbits. Mol Cell Biochem. 1996;157:149–55.
65.
BlaauwE, van NieuwenhovenFA, WillemsenP, DelhaasT, PrinzenFW, SnoeckxLH, et al. Stretch-induced hypertrophy of isolated adult rabbit cardiomyocytes. Am J Physiol Heart Circ Physiol. 2010;299:H780–7.
66.
BhadrirajuK, ChenCS. Engineering cellular microenvironments to improve cell-based drug testing. Drug Discov Today. 2002;7:612–20.
67.
ZhangYS, AlemanJ, ArneriA, BersiniS, PirainoF, ShinSR, et al. From cardiac tissue engineering to heart-on-a-chip: beating challenges. Biomed Mater. 2015;10:034006.
68.
TandonN, CannizzaroC, ChaoPH, MaidhofR, MarsanoA, AuHT, et al. Electrical stimulation systems for cardiac tissue engineering. Nat Protoc. 2009;4:155–73.
69.
ChiuLL, IyerRK, KingJP, RadisicM. Biphasic electrical field stimulation aids in tissue engineering of multicell-type cardiac organoids. Tissue Eng Part A. 2011;17:1465–77.
70.
LaughlinMH, TomanekRJ. Myocardial capillarity and maximal capillary diffusion capacity in exercise-trained dogs. J Appl Physiol. 1987;63:1481–6.
RadisicM, MaldaJ, EppingE, GengW, LangerR, Vunjak-NovakovicG. Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissue. Biotechnol Bioeng. 2006;93:332–43.
73.
VisoneR, TaloG, LopaS, RasponiM, MorettiM. Enhancing all-in-one bioreactors by combining interstitial perfusion, electrical stimulation, on-line monitoring and testing within a single chamber for cardiac constructs. Sci Rep. 2018;8:16944.
74.
HuhD, MatthewsBD, MammotoA, Montoya-ZavalaM, HsinHY, IngberDE. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–8.
75.
ProdanovL, JindalR, BaleSS, HegdeM, McCartyWJ, GolbergI, et al. Long-term maintenance of a microfluidic 3D human liver sinusoid. Biotechnol Bioeng. 2016;113:241–6.
76.
KimHJ, HuhD, HamiltonG, IngberDE. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip. 2012;12:2165–74.
77.
JangKJ, SuhKY. A multi-layer microfluidic device for efficient culture and analysis of renal tubular cells. Lab Chip. 2010;10:36–42.
78.
ZhangC, ZhaoZ, Abdul RahimNA, van NoortD, YuH. Towards a human-on-chip: culturing multiple cell types on a chip with compartmentalized microenvironments. Lab Chip. 2009;9:3185–92.
79.
EschMB, SmithAS, ProtJM, OleagaC, HickmanJJ, ShulerML. How multi-organ microdevices can help foster drug development. Adv Drug Deliv Rev. 2014;69-70:158–69.
80.
WilliamsonA, SinghS, FernekornU, SchoberA. The future of the patient-specific Body-on-a-chip. Lab Chip. 2013;13:3471–80.
81.
WikswoJP, BlockFE3rd, CliffelDE, GoodwinCR, MarascoCC, MarkovDA, et al. Engineering challenges for instrumenting and controlling integrated organ-on-chip systems. IEEE Trans Biomed Eng. 2013;60:682–90.
82.
DiMasiJA, GrabowskiHG, HansenRW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20–33.
83.
Van NormanGA. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach?JACC Basic Transl Sci. 2019;4:845–54.
84.
FranzenN, van HartenWH, RetelVP, LoskillP, van den Eijnden-van RaaijJ, MIJ. Impact of organ-on-a-chip technology on pharmaceutical R&D costs. Drug Discov Today. 2019;24:1720–4.
85.
WhitesidesGM. The origins and the future of microfluidics. Nature. 2006;442:368–73.
86.
LowLA, MummeryC, BerridgeBR, AustinCP, TagleDA. Organs-on-chips: into the next decade. Nat Rev Drug Discov. 2021;20:345–61.
87.
EschEW, BahinskiA, HuhD. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov. 2015;14:248–60.
WuQ, LiuJ, WangX, FengL, WuJ, ZhuX, et al. Organ-on-a-chip: recent breakthroughs and future prospects. Biomed Eng Online. 2020;19:9.
90.
JodatYA, KangMG, KiaeeK, KimGJ, MartinezAFH, RosenkranzA, et al. Human-Derived Organ-on-a-Chip for Personalized Drug Development. Curr Pharm Des. 2018;24:5471–86.
91.
OleagaC, BernabiniC, SmithAS, SrinivasanB, JacksonM, McLambW, et al. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep. 2016;6:20030.
92.
OleagaC, RiuA, RothemundS, LavadoA, McAleerCW, LongCJ, et al. Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system. Biomaterials. 2018;182:176–90.
93.
SchneiderO, ZeifangL, FuchsS, SailerC, LoskillP. User-Friendly and Parallelized Generation of Human Induced Pluripotent Stem Cell-Derived Microtissues in a Centrifugal Heart-on-a-Chip. Tissue Eng Part A. 2019;25:786–98.
94.
WengKC, KurokawaYK, HajekBS, PaladinJA, ShirureVS, GeorgeSC. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity. Tissue Eng Part C Methods. 2020;26:44–55.
95.
ChramiecA, TelesD, YeagerK, Marturano-KruikA, PakJ, ChenT, et al. Integrated human organ-on-a-chip model for predictive studies of anti-tumor drug efficacy and cardiac safety. Lab Chip. 2020;20:4357–72.
96.
MastikhinaO, MoonBU, WilliamsK, HatkarR, GustafsonD, MouradO, et al. Human cardiac fibrosis-on-a-chip model recapitulates disease hallmarks and can serve as a platform for drug testing. Biomaterials. 2020;233:119741.
97.
LeeJ, MehrotraS, Zare-EelanjeghE, RodriguesRO, AkbarinejadA, GeD, et al. A Heart-Breast Cancer-on-a-Chip Platform for Disease Modeling and Monitoring of Cardiotoxicity Induced by Cancer Chemotherapy. Small. 2021;17:e2004258.
98.
VealGJ, ColeM, ChinnaswamyG, SluddenJ, JamiesonD, ErringtonJ, et al. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. Eur J Cancer. 2016;55:56–64.
99.
Fexofenadine: new preparation. Terfenadine, without cardiotoxicity. Prescrire Int. 1999;8:11–3.
100.
AhmedAR, HombalSM. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Dermatol. 1984;11:1115–26.
CardinaleD, ColomboA, BacchianiG, TedeschiI, MeroniCA, VegliaF, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8.
103.
Cadeddu DessalviC, DeiddaM, MeleD, BassareoPP, EspositoR, SantoroC, et al. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention. J Cardiovasc Med (Hagerstown). 2018;19:315–23.
104.
KhanR, SheppardR. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology. 2006;118:10–24.
105.
MorimotoY, MoriS, SakaiF, TakeuchiS. Human induced pluripotent stem cell-derived fiber-shaped cardiac tissue on a chip. Lab Chip. 2016;16:2295–301.
106.
WatsonCJ, PhelanD, XuM, CollierP, NearyR, SmolenskiA, et al. Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-beta mediated fibrosis. Fibrogenesis Tissue Repair. 2012;5:9.
107.
LiC, HanR, KangL, WangJ, GaoY, LiY, et al. Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-alpha in myocardial infarction-induced cardiac fibrosis. Sci Rep. 2017;7:40523.
108.
HauserS, JungF, PietzschJ. Human Endothelial Cell Models in Biomaterial Research. Trends Biotechnol. 2017;35:265–77.
109.
SteinbrechtS, KonigR, SchmidtkeKU, HerzogN, ScheibnerK, Kruger-GengeA, et al. Metabolic activity testing can underestimate acute drug cytotoxicity as revealed by HepG2 cell clones overexpressing cytochrome P450 2C19 and 3A4. Toxicology. 2019;412:37–47.
110.
KammererS. Three-Dimensional Liver Culture Systems to Maintain Primary Hepatic Properties for Toxicological Analysis In vitro. Int J Mol Sci. 2021;22.
111.
AlimpertiS, MirabellaT, BajajV, PolacheckW, PironeDM, DuffieldJ, et al. Three-dimensional biomimetic vascular model reveals a RhoA, Rac1, and N-cadherin balance in mural cell-endothelial cell-regulated barrier function. Proc Natl Acad Sci U S A. 2017;114:8758–63.
112.
WangX, LeeJ, AliM, KimJ, LacerdaCMR. Phenotype Transformation of Aortic Valve Interstitial Cells Due to Applied Shear Stresses Within a Microfluidic Chip. Ann Biomed Eng. 2017;45:2269–80.
113.
ZeinaliS, BichselCA, HobiN, FunkeM, MartiTM, SchmidRA, et al. Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro. Angiogenesis. 2018;21:861–71.
114.
AhnJ, ChoCS, ChoSW, KangJH, KimSY, MinDH, et al. Investigation on vascular cytotoxicity and extravascular transport of cationic polymer nanoparticles using perfusable 3D microvessel model. Acta Biomater. 2018;76:154–63.
115.
KongM, LeeJ, YazdiIK, MiriAK, LinYD, SeoJ, et al. Cardiac Fibrotic Remodeling on a Chip with Dynamic Mechanical Stimulation. Adv Healthc Mater. 2019;8:e1801146.
116.
LiY, HuC, WangP, LiuY, WangL, PiQ, et al. Indoor nanoscale particulate matter-induced coagulation abnormality based on a human 3D microvascular model on a microfluidic chip. J Nanobiotechnology. 2019;17:20.
117.
Nemcovsky AmarD, EpshteinM, KorinN. Endothelial Cell Activation in an Embolic Ischemia-Reperfusion Injury Microfluidic Model. Micromachines (Basel). 2019;10.
118.
ZhaoY, RafatianN, WangEY, FericNT, LaiBFL, Knee-WaldenEJ, et al. Engineering microenvironment for human cardiac tissue assembly in heart-on-a-chip platform. Matrix Biol. 2020;85-86:189–204.
119.
AbudupataerM, ZhuS, YanS, XuK, ZhangJ, LuoS, et al. Aorta smooth muscle-on-a-chip reveals impaired mitochondrial dynamics as a therapeutic target for aortic aneurysm in bicuspid aortic valve disease. Elife. 2021;10.
120.
KobuszewskaA, KolodziejekD, WojasinskiM, CiachT, BrzozkaZ, JastrzebskaE. Study of Stem Cells Influence on Cardiac Cells Cultured with a Cyanide-P-Trifluoromethoxyphenylhydrazone in Organ-on-a-Chip System. Biosensors (Basel). 2021;11.
121.
GaengelK, GenoveG, ArmulikA, BetsholtzC. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29:630–8.
HeY, YaoY, TsirkaSE, CaoY. Cell-culture models of the blood-brain barrier. Stroke. 2014;45:2514–26.
124.
da Silva MeirellesL, BellagambaBC, CamassolaM, NardiNB. Mesenchymal stem cells and their relationship to pericytes. Front Biosci (Landmark Ed). 2016;21:130–56.
ButcherJT, SimmonsCA, WarnockJN. Mechanobiology of the aortic heart valve. J Heart Valve Dis. 2008;17:62–73.
127.
MongkoldhumrongkulN, LatifN, YacoubMH, ChesterAH. Effect of Side-Specific Valvular Shear Stress on the Content of Extracellular Matrix in Aortic Valves. Cardiovasc Eng Technol. 2018;9:151–7.
128.
ButcherJT, NeremRM. Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: effects of steady shear stress. Tissue Eng. 2006;12:905–15.
129.
ButcherJT, NeremRM. Valvular endothelial cells and the mechanoregulation of valvular pathology. Philos Trans R Soc Lond B Biol Sci. 2007;362:1445–57.
130.
ParanyaG, VinebergS, DvorinE, KaushalS, RothSJ, RabkinE, et al. Aortic valve endothelial cells undergo transforming growth factor-beta-mediated and non-transforming growth factor-beta-mediated transdifferentiation in vitro. Am J Pathol. 2001;159:1335–43.
131.
van de PolV, KurakulaK, DeRuiterMC, GoumansMJ. Thoracic Aortic Aneurysm Development in Patients with Bicuspid Aortic Valve: What Is the Role of Endothelial Cells?Front Physiol. 2017;8:938.
132.
MalashichevaA, KostinaA, KostarevaA, IrtyugaO, GordeevM, UspenskyV. Notch signaling in the pathogenesis of thoracic aortic aneurysms: A bridge between embryonic and adult states. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165631.
133.
HarrisonOJ, TorrensC, SalhiyyahK, ModiA, MoorjaniN, TownsendPA, et al. Defective NOTCH signalling drives smooth muscle cell death and differentiation in bicuspid aortic valve aortopathy. Eur J Cardiothorac Surg. 2019;56:117–25.
134.
MaY, IyerRP, JungM, CzubrytMP, LindseyML. Cardiac Fibroblast Activation Post-Myocardial Infarction: Current Knowledge Gaps. Trends Pharmacol Sci. 2017;38:448–58.
135.
SpinaleFG, FrangogiannisNG, HinzB, HolmesJW, KassiriZ, LindseyML. Crossing Into the Next Frontier of Cardiac Extracellular Matrix Research. Circ Res. 2016;119:1040–5.
136.
MaxwellSR, LipGY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol. 1997;58:95–117.
137.
EltzschigHK, EckleT. Ischemia and reperfusion–from mechanism to translation. Nat Med. 2011;17:1391–401.
138.
ZhangS, Shaw-BodenJ, BanzY, BongoniAK, TaddeoA, SpirigR, et al. Effects of C1 inhibitor on endothelial cell activation in a rat hind limb ischemia-reperfusion injury model. J Vasc Surg. 2018;68:209S–21Se2.
139.
ShinHS, ShinHH, ShudoY. Current Status and Limitations of Myocardial Infarction Large Animal Models in Cardiovascular Translational Research. Front Bioeng Biotechnol. 2021;9:673683.
140.
BatalovI, FeinbergAW. Differentiation of Cardiomyocytes from Human Pluripotent Stem Cells Using Monolayer Culture. Biomark Insights. 2015;10:71–6.
141.
DuelenR, SampaolesiM. Stem Cell Technology in Cardiac Regeneration: A Pluripotent Stem Cell Promise. EBioMedicine. 2017;16:30–40.
142.
KitsaraM, AgbulutO, KontziampasisD, ChenY, MenascheP. Fibers for hearts: A critical review on electrospinning for cardiac tissue engineering. Acta Biomater. 2017;48:20–40.
143.
DaoupharsM, KoufanyM, BenaniA, MarchalS, MerlinJL, NetterP, et al. Uncoupling of oxidative phosphorylation and Smac/DIABLO release are not sufficient to account for induction of apoptosis by sulindac sulfide in human colorectal cancer cells. Int J Oncol. 2005;26:1069–77.
AckermannM, KimYO, WagnerWL, SchuppanD, ValenzuelaCD, MentzerSJ, et al. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis. 2017;20:359–72.
146.
ZakeriA, KouhbananiMAJ, BeheshtkhooN, BeigiV, MousaviSM, HashemiSAR, et al. Polyethylenimine-based nanocarriers in co-delivery of drug and gene: a developing horizon. Nano Rev Ex. 2018;9:1488497.
147.
SinghB, MaharjanS, KimYK, JiangT, IslamMA, KangSK, et al. Targeted gene delivery via N-acetylglucosamine receptor mediated endocytosis. J Nanosci Nanotechnol. 2014;14:8356–64.
